Isolated trisomy 8 (+8) is a frequent cytogenetic abnormality in the myelodysplastic syndromes (MDS), but its characteristics are poorly reported. We performed a retrospective study of 138 MDS patients with isolated +8, classified or reclassified as MDS (excluding MDS/myeloproliferative neoplasm). Myeloproliferative (MP) features were defined by the repeated presence of one of the following: white blood cell count >10 9 10 9 /l, myelemia (presence of circulating immature granulocytes with a predominance of more mature forms) >2%, palpable splenomegaly. Fiftyfour patients (39Á1%) had MP features: 28 at diagnosis, 26 were acquired during evolution. MP forms had more EZH2 (33Á3% vs. 12Á0% in non-MP, P = 0Á047), ASXL1 (66Á7% vs. 42Á3%, P = 0Á048) and STAG2 mutations (77Á8% vs. 21Á7%, P = 0Á006). Median event-free survival (EFS) and overall survival (OS) were 25 and 27 months for patients with MP features at diagnosis, versus 28 (P = 0Á15) and 39 months (P = 0Á085) for those without MP features, respectively. Among the 57 patients who received hypomethylating agent (HMA), OS was lower in MP cases (13 months vs. 23 months in non-MP cases, P = 0.02). In conclusion, MP features are frequent in MDS with isolated +8. MP forms had more EZH2, ASXL1 and STAG2 mutations, responded poorly to HMA, and tended to have poorer survival than non-MP forms.
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Isolated trisomy 8 (+8) is a frequent cytogenetic abnormality in the myelodysplastic syndromes (MDS), but its characteristics are poorly reported. We performed a retrospective study of 138 MDS patients with isolated +8, classified or reclassified as MDS (excluding MDS/myeloproliferative neoplasm). Myeloproliferative (MP) features were defined by the repeated presence of one of the following: white blood cell count >10 9 10 9 /l, myelemia (presence of circulating immature granulocytes with a predominance of more mature forms) >2%, palpable splenomegaly. Fiftyfour patients (39Á1%) had MP features: 28 at diagnosis, 26 were acquired during evolution. MP forms had more EZH2 (33Á3% vs. 12Á0% in non-MP, P = 0Á047), ASXL1 (66Á7% vs. 42Á3%, P = 0Á048) and STAG2 mutations (77Á8% vs. 21Á7%, P = 0Á006). Median event-free survival (EFS) and overall survival (OS) were 25 and 27 months for patients with MP features at diagnosis, versus 28 (P = 0Á15) and 39 months (P = 0Á085) for those without MP features, respectively. Among the 57 patients who received hypomethylating agent (HMA), OS was lower in MP cases (13 months vs. 23 months in non-MP cases, P = 0.02). In conclusion, MP features are frequent in MDS with isolated +8. MP forms had more EZH2, ASXL1 and STAG2 mutations, responded poorly to HMA, and tended to have poorer survival than non-MP forms.
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The myelodysplastic syndromes (MDS) are clonal myeloid stem cell disorders, characterized by ineffective haematopoiesis, with increased bone marrow cellularity, myeloid lineage dysplasia, peripheral cytopenia, and by an increased risk of developing acute myeloid leukaemia (AML) (Ad es et al, 2014).
Isolated trisomy 8 (+8) is one of the most frequent cytogenetic abnormalities in MDS, representing 9-11% of de novo MDS with cytogenetic abnormality, and 5% of all MDS (Greenberg et al, 1997; Sol e et al, 2000; Mitelman et al, 2017) . Trisomy 8 is, however, not specific to MDS, but is also frequent in chronic myelomonocytic leukaemia (CMML) (Tang et al, 2014; Wassie et al, 2014) , AML (Paulsson et al, 2001; Wolman et al, 2002) and some myeloproliferative neoplasms (MPN) (especially primary myelofibrosis and to a lesser extent polycythaemia vera) (Gangat et al, 2008; Wassie et al, 2015; Barraco et al, 2017) .
Large numbers of MDS patients with isolated +8 have been included in the MDS patient series used in the design of MDS prognostic scoring systems, including the International Prognostic Scoring System (IPSS) and the revised IPSS (Greenberg et al, 1997 (Greenberg et al, , 2012 ; isolated +8 was found to be of "intermediate" prognosis in both scoring systems. On the other hand, to our knowledge, the haematological characteristics and results of specific treatments in MDS with isolated +8 have not been described in detail.
The aim of this study was to describe the characteristics of MDS with isolated trisomy 8, and their outcome with the main therapeutic approaches used in MDS.
Materials and methods

Study population
We performed a retrospective analysis of patients with MDS and isolated +8 diagnosed between 2001 and 2016 in 8 French centres of the Groupe Francophone des My elodysplasies (GFM) and included in the GFM MDS registry.
Diagnoses were reviewed and reclassified according to 2016 World Health Organization (WHO) classification (Arber et al, 2016) . Patients were included in the present study if they fulfilled the following criteria: (i) diagnosis of MDS according to the WHO 2016 classification revision; (ii) presence of isolated +8; (iii) exclusion of AML, well characterized myeloproliferative neoplasm (MPN; polycythaemia vera, essential thrombocythaemia, primary myelofibrosis) and MDS/MPN.
We defined myeloproliferative (MP) features as the repeated presence (in the absence of infection), and at diagnosis or during evolution, of one of the following criteria: (i) white blood cell (WBC) count >10 9 10 9 /l; (ii) circulating immature granulocytes with a predominance of more mature forms, i.e. myelocytes and metamyelocytes (myelemia) >2%; and/or (iii) palpable splenomegaly. Patients were evaluated for clinical and haematological parameters, percentage of metaphases with +8, IPSS (Greenberg et al, 1997) and revised IPSS (Greenberg et al, 2012) and, when available, the presence and type of somatic mutations.
Molecular analysis
As the diagnoses were made over a period of 15 years, molecular analysis was generally performed retrospectively on archival samples. Bone marrow mononuclear cells were purified on Ficoll gradient and processed for DNA extraction using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). Mutations in a selected panel of 22-54 genes (ASXL1, ATM, ATRX, BCOR, BCORL1, BRAF, BRCC3, CALR, CBL, CEBPA, CSF3R, CTCF, CUX1, DIS3, DNMT3A, DNMT3B, DOT1L, EP300, ETV6, EZH2, FLT3-TKD, GATA2, GNAS, IDH1, IDH2, JAK2, KIT, KMT2A (previously termed MLL), KMT2D (previously termed MLL2), KRAS, LAMB4, MPL, NF1, NIPBL, NPM1, NRAS, PHF6, PRPF8, PTPN11, RAD21, RIT1, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG1, STAG2, TET2, TP53, U2AF1, WT1, and ZRSR2) were screened by a next-generation sequencing (NGS) assay using the Ion AmpliSeq Library Kit 2.0 (384 reactions; Thermo FisherScientific, Carlsbad, CA).
Bioinformatic analysis
Base calls were generated by the Torrent Browser software (version 5.0.4) using the included variant caller with an additional plug-in (Thermo Fisher Scientific). The.bam and.vcf files were used for further analysis. The.vcf files were annotated with the Ion reporter software (Thermo Fisher Scientific) and processed for a second analysis of the indexed files using the Sequence Pilot software (4.2.1 version) (JSI Medical Systems, Ettenheim, Germany). Results were compared with a selection of variants to be further considered. For each variant, depth at the variant position (number of mutated reads and unmutated reads) was considered to calculate variant allele frequency.
Statistical analysis
Overall survival (OS) and event-free survival (EFS, defined as progression to AML or death) analyses were plotted using the Kaplan-Meier method. Chi-square test, Student's t-test and log-rank test were applied to calculate the significance of differences between groups, with a level of significance of P < 0Á05. Statistical analysis was performed using GraphPad Prism v7.00 for Windows (GraphPad Software, La Jolla, California, USA), and R version 3.4.1 for Windows (R Foundation for Statistical Computing, Vienna, Austria).
Results
Patient characteristics at diagnosis
A total of 138 patients with isolated +8 were eligible for evaluation. Their initial characteristics are shown in Table I . Median age was 75 years, and the male:female ratio was 1Á7. After revision according to WHO 2016 criteria, 44Á9% of patients were classified as MDS with excess blasts type 1 or 2 (MDS-EB-1 or -2), 39Á8% as MDS with single lineage dysplasia (MDS-SLD) or MDS with multilineage dysplasia (MDS-MLD), 10Á9% as MDS with ringed sideroblasts (MDS-RS), and 4Á3% as MDS unclassifiable (MDS-U). IPSS and R-IPSS are shown in Table I . Table I . Baseline characteristics of patients with MDS and isolated trisomy 8 (and MDS/MPN-U with isolated trisomy 8).
All patients (n = 138)
MP patients (at diagnosis or during evolution) (n Eighteen patients with MDS characteristics and isolated +8 but with WBC count >13 9 10 9 /l and/or platelets >450 9 10 9 /l, reclassified per WHO criteria as MDS/MPN (17 as MDS/MPN unclassifiable and 1 as MDS/MPN with ring sideroblasts and thrombocytosis), were excluded.
Frequency of MP features
Fifty-four patients (39Á1%) had MP features, 28 (20Á3%) of them at diagnosis and 26 (18Á8%) during evolution, with a median interval of 13 months between diagnosis and onset of MP features. Patients were classified as MP because of a WBC count >10 9 10 9 /l (but below 13 9 10 9 /l) in 15 cases (10Á9% of the total patient number), myelemia in 40 (29Á0%) and palpable splenomegaly in 18 (13Á0%). Among the 54 patients classified as MP, 37 had one criterion, 15 had two and 2 had three criteria.
The MP and non-MP groups did not significant differ in other baseline haematological parameters, except for a significantly greater male predominance in the MP group (male:female ratio 2Á9 vs. 1Á2 in the non-MP group, P = 0Á002) and a higher percentage of metaphases with trisomy 8 in the MP group (58Á9% vs. 47Á0% in the non-MP group, P = 0Á043) ( Table I ). In the MP group, baseline characteristics of patients with 2 or 3 MP criteria did not significantly differ from those of patients with one MP criterion, although a somewhat higher percentage of metaphases with trisomy 8 was seen in the former group (65Á9% vs. 55Á9%, P = 0Á32).
Five patients who initially had non-MP features were karyotyped again when they developed MP features. Two already had >80% metaphases with trisomy 8, while the remaining 3 patients significantly increased their proportion of metaphases with trisomy 8.
Mutational analysis
Mutational analysis by NGS was performed in 77 patients (Table II) . Patients with MP forms at NGS analysis had significantly more EZH2 (33Á3% vs. 12Á0% in non-MP, P = 0Á047), ASXL1 (66Á7% vs. 42Á3%, P = 0Á048) and STAG2 mutations (77Á8% vs. 21Á7%, P = 0Á006).
Response to treatment and survival
Treatment consisted of erythropoiesis stimulating agents (ESA) in 79 patients (17 MP forms, 62 non-MP forms), hypomethylating agents (HMA) in 57 patients (21 MP forms, 36 non-MP forms), hydroxycarbamide in 11 patients, intensive chemotherapy in 6 patients, and allogeneic stem cell transplantation in 12 patients. The response rate to ESA was 67Á3%, and was slightly lower in MP patients (at time of treatment onset) than in non-MP patients (44Á4% vs. 72Á1%, P = not significant [NS] ). The response rate to HMA (including complete remission, partial remission, marrow complete remission and haematological improvement) was Table II 33Á3%, i.e., 31Á3% in MP patients at the time of treatment onset, vs. 34Á4% in non-MP patients, P = NS). Median follow-up was 20 months. Progression to AML was seen in 7 patients with MP features at diagnosis (25Á0%) and in 26 without MP features at diagnosis (23Á6%). Three patients progressed to CMML after a median of 18 months. Median EFS ("events" being defined as progression to AML or death) was 25 months for the whole cohort, 25 months for patients with MP features at diagnosis, and 28 months for patients who had no MP features at diagnosis (P = 0Á15) (Fig 1) .
Median OS was 33 months for the whole cohort, 27 months for patients with MP features at diagnosis, and 39 months for patients without MP features at diagnosis (P = 0Á085) (Fig 2) . Median OS for patients treated with HMA was 21 months from the onset of treatment, 13 months in MP forms and 23 months in non-MP forms (P = 0.02) (Fig 3A) . For patients who received allogeneic stem cell transplantation, median OS was 9 months, and 3-year survival was 25Á0% (Fig 3B) .
Comparisons between the MP group and MDS/MPN-U with isolated +8
As seen in Tables I and II , no significant differences in baseline characteristics, including mutational status, were found between the MP group and the 17 patients with isolated +8 excluded from the study because of baseline WBC count >13 9 10 9 /l, and reclassified as MDS/MPN-U. One exception however was the female predominance in MDS/MPN-U (male:female = 0Á4) and the male predominance (male:female = 2Á9) in the MP group (P < 0Á001). In MDS/MPN-U patients with isolated +8, the response rates to ESA and HMA were 0/3 (0%) and 1/4 patients (20%) respectively, 23Á5% of the patients progressed to AML and median OS was 19 months. Those results did not significantly differ from the results in the MP group of MDS with isolated +8, although the numbers of patients were small for comparisons.
Discussion
Our main finding was the presence at diagnosis or during evolution of MP features in 39Á2% of the evaluated cases.
The association between isolated +8 and myeloproliferation is already known in other myeloid neoplasms, including CMML (Tang et al, 2014) and primary myelofibrosis (Wassie et al, 2015) but, to our knowledge, had not been reported in MDS (Paulsson & Johansson, 2007) . Patients with MP features had a larger male predominance and a higher mean percentage of metaphases with +8. The relationship between +8 and myeloproliferation has no clear pathophysiological explanation. Trisomy 8 could play a role through a gene dosage effect: some microarray studies in AML show that trisomy 8 leads to a higher expression of genes located on chromosome 8, but no consistent pattern of genes was identified and, in particular, no gene was associated with myeloproliferation (Virtaneva et al, 2001; Schoch et al, 2006) . On the other hand, trisomy 8 is a frequent secondary cytogenetic event in a wide spectrum of myeloid disorders, including aplastic anaemia (Mikhailova et al, 1996; Sloand et al, 2005) , and low risk MDS with del 5q treated with lenalidomide (Fenaux et al, 2011) .
A higher frequency of ASXL1, EZH2 and STAG2 mutations (genes not located on chromosome 8) was found in patients with MP features. ASXL1 and EZH2 mutations are more frequent in MDS/MPN than in MDS (Gelsi-Boyer et al, 2009; Ernst et al, 2010; Haferlach et al, 2014) , and ASXL1 is known to be associated with MP features in CMML (Itzykson et al, 2013; Patnaik et al, 2014) , while cohesin knockdown mice (including for STAG2) develop a clinical picture resembling myeloproliferative neoplasm (Mullenders et al, 2015) . However, ASXL1, EZH2 or STAG2 mutations are not associated with MP features in MDS (Wang et al, 2013; Thota et al, 2014; Wu et al, 2016) . In contrast to CMML (and juvenile myelomonocytic leukaemia) (Kratz et al, 2005; Kohlmann et al, 2010; P erez et al, 2010) , mutations of NRAS, KRAS, CBL and PTPN11 were very rare in our cohort, possibly indicating different pathophysiological mechanisms between disorders that have a myeloproliferative component in common.
With regards to treatment, overall response to HMA was low (31Á3% in MP forms and 34Á4% in non-MP forms). Median OS was 23 months in non-MP forms, as previously published in higher risk MDS with +8 treated with HMAs (S ebert et al, 2017), but only 13 months in MP forms, suggesting that those forms respond very poorly to HMAs. There was also a trend for lower response rate to ESA in MP patients compared to non-MP patients.
There was no significant different rate of progression to AML in the 2 groups, but a trend for lower OS in the MP than in the non-MP forms. The OS found in this study was consistent with previous results in MDS patients with isolated +8 (Saumell et al, 2012) .
Finally, although numbers remained low, the 17 patients with isolated +8 reclassified as MDS/MPN-U based on a baseline WBC count greater than 13 9 10 9 /l had features and outcome that looked similar to those of the MP group of patients studied here, except the unexpected difference in gender predominance that has no clear explanation. This possibly suggested that the cut-off point of 13 9 10 9 /l for WBC count chosen to distinguish MDS with isolated +8 and MDS/MPN-U with isolated +8, as expected, is somewhat arbitrary, and that those patients may represent a continuum with a tendency for MP features. Although retrospective, our study is the first to suggest a high frequency of MP features either at diagnosis or during evolution in MDS with isolated + 8. Patients with MP features had a higher frequency of EZH2, ASXL1 and STAG2 mutations, responded poorly to HMAs, and had a trend for lower EFS and OS than those of non-MP forms.
